PSU19 Does the Novel Renal Marker NGAL (Neutrophil Gelatinase-Associated Lipocalin) Result in Cost Savings in Patients With Renal Impairment Following Cardiac Surgery?
Nov 1, 2012, 00:00 AM
10.1016/j.jval.2012.08.1177
https://www.valueinhealthjournal.com/article/S1098-3015(12)02890-2/fulltext
Section Title :
Surgery
Section Order :
678
First Page :
A405
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02890-2&doi=10.1016/j.jval.2012.08.1177